To systematically review and synthesize the safety and efficacy of coronavirus disease‐2019
(COVID‐19) vaccines in children and adolescents. PubMed, EMBASE, Web of Science …

Children and adolescents form a large proportion of societies and play an important role in
the transmission of COVID-19. On the other hand, their education, mental and physical …

Background Infants younger than 6 months of age are at high risk for complications of
coronavirus disease 2019 (Covid-19) and are not eligible for vaccination. Transplacental …

The Pfizer-BioNTech vaccine, currently authorized for persons aged≥ 5 years, provides a
high level of protection against severe COVID-19 in persons aged 12–18 years. Vaccine …

Background Spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
B. 1.1. 529 (omicron) variant, which led to increased US hospitalizations for coronavirus …

Background The increasing incidence of pediatric hospitalizations associated with
coronavirus disease 2019 (Covid-19) caused by the B. 1.617. 2 (delta) variant of severe …

Neutralization capacity of antibodies against Omicron after a prior SARS-CoV-2 infection in
children and adolescents is not well studied. Therefore, we evaluated virus-neutralizing …

In the UK, COVID-19 vaccination for adults began in December, 2020. 1 Because children
and adolescents have a low risk of severe COVID-19 and due to concerns about rare but …

Background Male patients ages 12–17 years have an elevated risk of mRNA vaccination‐
associated myo/pericarditis. A risk‐benefit analysis of first and second doses of mRNA …

Background Vaccination of children and young people against SARS-CoV-2 is
recommended in some countries. Scarce data have been published on immune responses …